Literature DB >> 20136956

Targeting circulatory dysfunction in cirrhosis: terlipressin and the hepatorenal syndrome.

Adam G Testro, Peter W Angus.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20136956     DOI： 10.1111/j.1440-1746.2009.06034.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN： 0815-9319            Impact factor:   4.029


× No keyword cloud information.
  2 in total

1.  Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis.

Authors:  Lawrence Mj Best; Suzanne C Freeman; Alex J Sutton; Nicola J Cooper; Eng-Loon Tng; Mario Csenar; Neil Hawkins; Chavdar S Pavlov; Brian R Davidson; Douglas Thorburn; Maxine Cowlin; Elisabeth Jane Milne; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2019-09-12

2.  Initial serum sodium concentration determines the decrease in sodium level after terlipressin administration in patients with liver cirrhosis.

Authors:  Yeo-Jin Kang; Eun Jin Bae; Kyungo Hwang; Dae-Hong Jeon; Ha Nee Jang; Hyun Seop Cho; Se-Ho Chang; Dong Jun Park
Journal:  Springerplus       Date:  2013-10-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.